AAMU
PDSB icon

Amundi Asset Management US’s PDS Biotechnology PDSB Stock Holding History

Amundi Asset Management US’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-3,920
Closed -$64K – 1651
2018
Q3 		$64K Hold
3,920
– – ﹤0.01% 1550
2018
Q2 		$81K Buy
+3,920
New +$81.8K ﹤0.01% 1479

Other funds holding PDSB

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Amundi Asset Management US's PDSB Position: Q4 2018 in Review

Amundi Asset Management US sold out of PDS Biotechnology (PDSB) in Q4 2018, closing a stake of 3,920 shares — an estimated $64K sold.

Amundi Asset Management US first reported a position in PDSB in Q2 2018 and held it in 2 quarters. The position peaked at $81K in Q2 2018. 31 funds tracked by Wall St. Rank hold PDSB as of Q4 2018.

  • Amundi Asset Management US reported no remaining PDS Biotechnology position as of Q4 2018 after selling out during the quarter.
  • Amundi Asset Management US sold 3,920 PDS Biotechnology shares in Q4 2018, an estimated $64K.
  • Amundi Asset Management US first reported a position in PDS Biotechnology in Q2 2018 and held it in 2 quarters.
  • Amundi Asset Management US's PDS Biotechnology position peaked at $81K in Q2 2018.
  • 31 funds tracked by Wall St. Rank held PDS Biotechnology as of Q4 2018.

Based on Amundi Asset Management US's 13F filing for Q4 2018, filed 14 Feb 2019.